Mirna Therapeutics, an Austin-based biotechnology company focused on the development and commercialization of miRNA therapeutics, has announced Sinil Kim, M.D. as the company’s new Vice President of Oncology and Chief Medical Officer.
Dr. Kim will be leading the company’s clinical efforts in the development of MRX34, Mirna’s first cancer product candidate, which also recently became the first micro-RNA product to begin clinical trials in cancer.
Paul Lammers, M.D., President and Chief Executive Officer of Mirna is quoted as saying:
“Dr. Kim joins Mirna at an exciting time in our company’s growth, as we have just successfully initiated our MRX34 Phase I trial and are looking forward to further growth and maturation of our proprietary micro-RNA discovery platform and preclinical pipeline. The depth and breadth of Sinil’s clinical and regulatory expertise in oncology, as well as his reputation as a respected industry executive responsible for successfully developing multiple marketed oncology products, will be of significant value to our clinical team as we work together to strengthen our leadership in the development of miRNA-based therapeutics as a promising new class of anticancer agents.”
In Dr. Kim’s long list of accomplishments prior to signing on to work with Mirna, he formerly worked as Senior Director at Pfizer Inc. in San Diego, CA. In addition, he also served as Director of Clinical Oncology at Bristol-Myers Squibb Company, and co-founder of DepoTech where he helped develop a number of novel liposomal drugs.
If you’d like to read more on Mirna’s first advancement in MicroRNA cancer treatment, click here.